Spots Global Cancer Trial Database for Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Official Title: An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas
Study ID: NCT02611700
Conditions
Study Description
Brief Summary: This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel+cisplatin（TP) compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.
Detailed Description: This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with TP compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.The main endpoint is OS.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
AnHui Provincial Hospital, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Chinese PLA General Hospital Medical School of Chinese PLA, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
The 307 Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center Sun Yat-Sen University Cancer Hospital, Guangzhou city, Guangdong, China
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
HuNan Cancer Hospital, Changsha, Hunan, China
JiangSu Province Hospital, Nanjing, Jiangsu, China
Affiliated Hospital ,JiangNan University, Wuxi, Jiangsu, China
Jilin Cancer Hospital, Changchun, Jilin, China
LiaoNing Cancer Hospital, Shenyang, Liaoning, China
Changhai Hospital of Shanghai, Shanghai, Shanghai, China
Rui Jin Hospital Shanghai Jiao Tong University School Of Medicine, Shanghai, Shanghai, China
Zhongshan hospital of fudan university, Shanghai, Shanghai, China
The First Affiliated of Xi'an Communication University, Xi'an, Shanxi, China
XiJing Hospital, Xi'an, Shanxi, China
West China Hospital,SiChuan University, Chengdu, Sichuan, China
TianJin Medical University Cancer Institute and Hospital, TianJin, Tianjin, China
Sir Run Run Shaw Hostpital School of Medicine,Zhejiang University, Hangzhou, Zhejiang, China
The second Affiliated hospital of Zhejiang University School o, Hangzhou, Zhejiang, China
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Lin Shen, Dr
Affiliation: Peking University Cancer Hospital & Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
